Mody, Prapti H. http://orcid.org/0000-0002-5530-7785
Dos Santos, Natalia L. http://orcid.org/0000-0003-2385-1900
Barron, Luz R. http://orcid.org/0000-0003-3797-3423
Price, Theodore J. http://orcid.org/0000-0002-6971-6221
Burton, Michael D. http://orcid.org/0000-0002-0628-824X
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NS096030, NS065926)
American Pain Society
Rita Allen Foundation
University of Texas
Article History
Received: 27 March 2020
Accepted: 18 June 2020
First Online: 1 July 2020
Compliance with ethical standards
:
: The authors except T.J.P. declare no conflict of interest. T.J.P. is a cofounder of 4E Therapeutics, a company developing MNK inhibitors for neuropathic pain. 4E Therapeutics played no role in funding the study.
: All procedures were in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the University of Texas at Dallas Institutional Animal Care and Use Committee protocols 15-15 and 16-07.
: All authors have reviewed the contents of the manuscript being submitted and approve of its contents and validate the accuracy of the data.
: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
: Not applicable.